

In the claims:

1. (currently amended) A method of ~~preventing~~ reducing complement-mediated cytotoxicity in a mammal which comprises  
  
identifying a mammal at risk of developing complement-mediated cytotoxicity; and  
  
administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 ~~prevents~~ reduces complement-mediated cytotoxicity in said mammal.
  
2. (original) The method of claim 1, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100µg/kg body weight.
  
3. (currently amended) A method of ameliorating complement-mediated cytotoxicity in a mammal which comprises  
  
identifying a mammal at risk of developing complement-mediated cytotoxicity; and  
  
administering, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 ~~prevents~~ ameliorates complement-mediated cytotoxicity in said mammal.
  
4. (original) The method of claim 4, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100µg/kg body weight.
  
5. (original) The method of claim 4, wherein the interleukin-11 is administered for three days beginning on the day of the tissue transplant.

6. (currently amended) A method of treating complement-mediated cytotoxicity in a mammal which comprises

identifying a mammal with complement-mediated cytotoxicity and

administering to said mammal a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 ~~prevents~~ reduces complement-mediated cytotoxicity in said mammal.

7. (original) The method of claim 7, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100µg/kg body weight.

8. (currently amended) The method of claim 7, wherein the interleukin-11 is administered daily until improvement of the ~~immune~~ complement- mediated cytotoxicity disorder is observed.

9. (currently amended) The method of claim 7, wherein the interleukin-11 is administered daily until remission of the ~~immune~~ complement-mediated disorder is observed.

10. (previously added) The method of claim 1 wherein said mammal is a human.

11. (previously added) The method of claim 6 wherein said mammal is a human.

Claims 12-20 (cancelled)